These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32839045)

  • 1. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
    J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
    Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
    Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
    Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
    Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
    Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
    Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
    Uemura H; Uchida Y; Kouyama JI; Naiki K; Tsuji S; Sugawara K; Nakao M; Motoya D; Nakayama N; Imai Y; Tomiya T; Mochida S
    J Gastroenterol; 2019 May; 54(5):459-470. PubMed ID: 30612205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
    Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
    Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
    Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
    Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
    Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
    Aliment Pharmacol Ther; 2024 Jul; 60(2):201-211. PubMed ID: 38695095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
    Ruwayni AA; AlObary EE; Alyahya KM
    Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
    Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Effectiveness and Safety of Glecaprevir/Pibrentasvir for the Treatment of Chronic Hepatitis C: A Prospective Cohort Study in Portugal.
    Vera J; Gomes A; Póvoas D; Seixas D; Maltez F; Pedroto I; Maia L; Mota M; Vieira MJ; Manata MJ; Ferreira P; Lino S; Pereira Guedes T; Barradas V; Marques N
    Acta Med Port; 2024 May; 37(5):323-333. PubMed ID: 38325411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
    Madsen LW; Christensen PB; Fahnøe U; Pedersen MS; Bukh J; Øvrehus A
    Liver Int; 2021 Nov; 41(11):2601-2610. PubMed ID: 34154034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.